BackStandard BioTools Overview

Standard BioTools Current Cash

Track Standard BioTools's current cash ($270M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$270.03M
70.24% YoYΔ $111.41M vs prior year quarter

Peer trimmed avg / median

Loading

Standard BioTools Current Cash History

Loading

Standard BioTools vs. peers: Current Cash Comparison

Loading

Standard BioTools Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Standard BioTools (LAB) FAQ

As of the most recent data (June 2026), LAB shows a current cash of $270M. That compares with $160M in the prior-year period — up 70.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LAB's current cash is now $270M (was $160M) — a 70.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Standard BioTools is outperforming or lagging.

Tracking LAB's current cash over time shows whether Standard BioTools is scaling, shrinking, or reshaping that part of the business. The current reading is $270M That compares with $160M in the prior-year period — up 70.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Standard BioTools's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $270M) with ownership activity and broader fundamentals.

Standard BioTools's current cash is $270M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.